Itraconazole and Paroxetine Interaction Management
The combination of itraconazole and paroxetine can be used together, but requires close monitoring for increased paroxetine levels and potential toxicity, as itraconazole significantly increases paroxetine bioavailability by approximately 1.5-fold through P-glycoprotein inhibition.
Mechanism of Interaction
Itraconazole acts as a P-glycoprotein inhibitor in the gut, which increases paroxetine absorption and bioavailability 1. The research demonstrates that itraconazole increases paroxetine peak plasma concentration (Cmax) by 1.3-fold and area under the curve (AUC) by 1.5-fold 1. While itraconazole is primarily known for CYP3A4 inhibition 2, the interaction with paroxetine appears predominantly mediated through gut transporter inhibition rather than hepatic metabolism 1.
Clinical Management Strategy
Initial Assessment
- Review cardiac risk factors: Both agents can prolong QT interval. Paroxetine guidelines note interactions with drugs causing QT prolongation 3, and azole antifungals carry similar warnings 2
- Baseline monitoring: Obtain ECG if cardiac risk factors present, liver function tests, and assess for bleeding risk (paroxetine increases bleeding risk, especially with NSAIDs) 3
Dosing Adjustments
If starting itraconazole in a patient already on paroxetine:
- Consider reducing paroxetine dose by 25-30% when initiating itraconazole to account for the 1.5-fold increase in exposure 1
- Monitor closely for paroxetine toxicity: increased sedation, tremor, nausea, or serotonergic symptoms 3
If starting paroxetine in a patient on itraconazole:
- Begin with lower paroxetine doses (10 mg/day instead of standard 20 mg/day) 4
- Titrate more slowly than usual, waiting at least 2 weeks between dose increases
Monitoring Requirements
Itraconazole therapeutic drug monitoring (TDM):
- Measure itraconazole trough levels after 7-14 days of therapy 2, 5
- Target therapeutic range: ≥0.5-1.0 mg/L (sum of itraconazole + hydroxy-itraconazole metabolite) 5
- Subtherapeutic levels are common, particularly in younger patients 6
Clinical monitoring:
- Assess for paroxetine adverse effects at 1-2 weeks after starting combination: excessive sedation, tremor, gastrointestinal symptoms, confusion 3
- Monitor for serotonin syndrome symptoms within first 24-48 hours of dose changes: mental status changes, neuromuscular hyperactivity (tremors, clonus), autonomic instability 3
- ECG monitoring if QT prolongation risk factors present 3, 2
Important Caveats
Psychiatric medication considerations:
- Paroxetine is metabolized by CYP2D6 (not CYP3A4), which explains why the interaction is primarily through P-glycoprotein rather than hepatic metabolism 3, 1
- Fluoxetine, paroxetine, and sertraline are CYP2D6 inhibitors themselves, but this is not relevant to the itraconazole interaction 3
Itraconazole absorption factors:
- Itraconazole capsules require acidic pH for absorption; take with food 7, 8
- Proton pump inhibitors or H2 blockers significantly reduce itraconazole absorption
- Solution formulation has better bioavailability than capsules 6
Alternative considerations:
- If the interaction proves problematic, consider switching to an alternative antifungal with less drug interaction potential (e.g., echinocandin class) 2
- Among SSRIs, citalopram/escitalopram have the least CYP450 interactions and may be preferable alternatives to paroxetine if antidepressant switch is feasible 3
Duration of Interaction
The interaction persists throughout concurrent therapy. After discontinuing itraconazole, allow at least 2 weeks for complete elimination before returning to standard paroxetine dosing, as itraconazole has a long half-life and its metabolites persist 9, 10.